% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Certa:300096,
      author       = {F. Certa and P. A. Horn and J. Keyl and B. Mende and S.
                      Lueong$^*$ and T. Hilser and S. Theurer and I. Virchow and
                      Y. Zaun and M. Pogorzelski and M. Metzenmacher and H.
                      Kalkavan$^*$ and S. Kasper and M. Schuler and M. Wiesweg and
                      G. Zaun},
      title        = {{ABO}-{B}lood {G}roup {A}ssociates {W}ith {S}urvival
                      {O}utcomes in {P}atients {W}ith {M}etastatic {N}on-{S}mall
                      {C}ell {L}ung {C}ancer {T}reated {W}ith {P}embrolizumab
                      {M}onotherapy.},
      journal      = {Thoracic cancer},
      volume       = {16},
      number       = {6},
      issn         = {1759-7706},
      address      = {Hoboken, NJ ˜[u.a.]œ},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2025-00596},
      pages        = {e70037},
      year         = {2025},
      abstract     = {In patients with metastatic non-small cell lung cancer
                      (NSCLC) with high programmed death-ligand 1 (PD-L1)
                      expression, there is still a lack of biomarkers to identify
                      patients with maximum benefit from first-line treatment with
                      checkpoint inhibitor therapy (CIT) alone. This work examines
                      the impact of different ABO blood groups (BG) on the
                      response to CIT monotherapy.Retrospective analysis of
                      patients with stage IV NSCLC and high PD-L1 expression
                      (tumor proportional score/TPS ≥ $50\%),$ receiving
                      first-line therapy with pembrolizumab alone or in
                      combination with chemotherapy at the West German Cancer
                      Center from 2017 to 2022. Study endpoints were overall
                      survival (OS) and progression-free survival (PFS).Eighty-two
                      patients were included in the analysis. Twenty-two patients
                      $(27\%)$ received first-line therapy with pembrolizumab
                      alone (monoimmunotherapy cohort/MIC), of which seven
                      patients $(32\%)$ had BGO. Sixty patients $(73\%)$ were
                      treated with pembrolizumab combined with platinum-based
                      chemotherapy (chemoimmunotherapy cohort/CIC), of which 38
                      $(63\%)$ had BGO. In MIC, younger age and BGO were
                      independent predictors of favorable OS (BGO vs. other
                      ABO-BG: HR 0.22, $95\%$ CI: 0.1-0.9; p = 0.037; median OS 62
                      versus 19 months) and PFS (BGO vs. other ABO-BG: HR 0.21,
                      $95\%$ CI: 0.1-0.8; p = 0.024; median PFS 39 vs. 4 months).
                      There was no significant impact of ABO-BG in patients
                      treated with CIC. In support, a historical control group
                      treated with chemotherapy alone also showed no prognostic
                      impact of the ABO-BG.BGO associates with favorable survival
                      in patients with NSCLC receiving pembrolizumab monotherapy,
                      but not in patients with chemo-immunotherapy or
                      chemotherapy. Further validation of this promising strategy
                      for personalized decision-making is warranted.},
      keywords     = {Humans / Antibodies, Monoclonal, Humanized: therapeutic use
                      / Carcinoma, Non-Small-Cell Lung: drug therapy / Carcinoma,
                      Non-Small-Cell Lung: mortality / Carcinoma, Non-Small-Cell
                      Lung: pathology / Lung Neoplasms: drug therapy / Lung
                      Neoplasms: mortality / Lung Neoplasms: pathology / Male /
                      Female / ABO Blood-Group System / Retrospective Studies /
                      Middle Aged / Aged / Adult / Aged, 80 and over / Prognosis /
                      Antineoplastic Agents, Immunological: therapeutic use /
                      Survival Rate / blood group (Other) / checkpoint inhibitor
                      (Other) / non‐small cell lung cancer (Other) / predictive
                      biomarkers (Other) / pembrolizumab (NLM Chemicals) /
                      Antibodies, Monoclonal, Humanized (NLM Chemicals) / ABO
                      Blood-Group System (NLM Chemicals) / Antineoplastic Agents,
                      Immunological (NLM Chemicals)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40114329},
      pmc          = {pmc:PMC11925720},
      doi          = {10.1111/1759-7714.70037},
      url          = {https://inrepo02.dkfz.de/record/300096},
}